Development and sale of new regenerative-medicine systems and contract cell-culture processing
First written in FY2018. 4 of 6 entries say "Restated". Latest entry: 2026-08-18.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- 2026-08-18AdvancedPresentation materials for financial results
「The order project for Thailand’s MEDEZE is scheduled to commence by the end of 2026」
The order for an automated cell-culture system for an autologous cell bank in the regenerative-medicine field, and its planned start-up timing, are specified. - FY2023RestatedAnnual report
「In the regenerative medicine systems business, which we have been focusing on in recent years, we support research into advanced medical technologies through industry-academia-government collaboration, primarily via joint research and development with universities and startups and cooperation with academic programs. At the same time, we are developing products to establish the mass-production capabilities needed to commercialize regenerative medicine.」
The company reiterates joint research and development with universities and startups, industry-academia-government collaboration and product development aimed at establishing mass-production capabilities. - FY2022RestatedAnnual report
「In the regenerative medicine systems business, which we have been focusing on in recent years, we support research into advanced medical technologies through industry-academia-government collaboration, primarily via joint research and development with universities and startups and cooperation with academic programs. At the same time, we are developing products to establish the mass-production capabilities needed to commercialize regenerative medicine.」
The company continues joint research and development with universities and startups, industry-academia-government collaboration and product development aimed at establishing mass-production capabilities. - FY2021RestatedAnnual report
「In the regenerative medicine systems business, which we have been focusing on in recent years, we support research into advanced medical technologies through industry-academia-government collaboration, primarily via joint research and development with universities and startups and cooperation with academic programs. At the same time, we are developing products to establish the mass-production capabilities needed to commercialize regenerative medicine.」
The company continues joint research and development, industry-academia-government collaboration and product development aimed at establishing mass-production capabilities in the regenerative medicine field. - FY2020RestatedAnnual report
「In the regenerative medicine systems business, which we have been focusing on in recent years, we support research into advanced medical technologies through industry-academia-government collaboration, primarily via joint research and development with universities and startups and cooperation with academic programs. At the same time, we are developing products to establish the mass-production capabilities needed to commercialize regenerative medicine.」
For regenerative medicine systems, the company specifically describes joint research and development, industry-academia-government collaboration and product development aimed at establishing mass-production capabilities. - FY2018First statedAnnual report
「In regenerative medicine systems, we will develop and sell new models and equipment, while also operating a contract cell-culture processing business.」
In the field of regenerative medicine, the company has for the first time identified as a standalone issue its policy of pursuing new model development, equipment sales and contract cell-culture processing.